Neuropeptides in learning and memory processes with focus on galanin

European Journal of Pharmacology

Volumn 626, Issue 1, 2010, Pages 9-17

  Ögren, Sven Ove ^a   Kuteeva, Eugenia ^a   Elvander Tottie, Elin ^a   Hökfelt, Tomas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Coexistence; Galanin; Hippocampus; Learning and memory; Neuropeptide

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; 4 AMINOBUTYRIC ACID; 8 (2,3,3A,4,5,6 HEXAHYDRO 1H PHENALEN 1 YL) 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DECAN 4 ONE; ANTIDEPRESSANT AGENT; BETA ENDORPHIN; BOMBESIN; CHOLECYSTOKININ; CORTICOTROPIN RELEASING FACTOR; DYNORPHIN; DYNORPHIN A; DYNORPHIN B; ENDORPHIN; GALANIN; GALANIN ANTAGONIST; GALANIN RECEPTOR 1; GALANIN RECEPTOR 2; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE Y; NEUROTRANSMITTER; NOCICEPTIN; NORBINALTORPHIMINE; SOMATOSTATIN; SUBSTANCE P; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALZHEIMER DISEASE; AVERSIVE BEHAVIOR; COGNITIVE DEFECT; DEPRESSION; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; GABAERGIC SYSTEM; HIPPOCAMPUS; HUMAN; LEARNING; LEARNING DISORDER; LOW DRUG DOSE; MEMORY CONSOLIDATION; MEMORY DISORDER; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NEUROENDOCRINE SYSTEM; NEUROMODULATION; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REVIEW; SPATIAL MEMORY; SPECIES DIFFERENCE;

ANIMALS; COGNITION; GALANIN; HIPPOCAMPUS; HUMANS; MEMORY; NEUROPEPTIDES;

EID: 70649114504     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.09.070     Document Type: Review

References (115)

1. Agnati L.F., Bjelke B., and Fuxe K. Volume versus wiring transmission in the brain: a new theoretical frame for neuropsychopharmacology. Med. Res. Rev. 15 (1995) 33-45
2. Bailey K.R., Pavlova M.N., Rohde A.D., Hohmann J.G., and Crawley J.N. Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze. Pharmacol. Biochem. Behav. 86 (2007) 8-20
3. Bakalkin G., Bazov I., Yakovleva T., Kuntic V., Sheedy D., Garrick T., Harper C., Ögren S.O., and Kuzmin A. Alcoholism-associated molecular adaptations in endogenous opioids in brain neurocognitive circuits: human and animal correlates. Eur. Neuropsychopharmacol. 18 Suppl. 4 (2008) S194
4. Barr A.M., Kinney J.W., Hill M.N., Lu X., Biros S., Rebek Jr. J., and Bartfai T. A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests. Neurosci. Lett. 405 (2006) 111-115
5. Branchek T.A., Smith K.E., Gerald C., and Walker M.W. Galanin receptor subtypes. Trends Pharmacol. Sci. 21 (2000) 109-117
6. Chan-Palay V. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. J. Comp. Neurol. 273 (1988) 543-557
7. Civelli O. The orphanin FQ/nociceptin (OFQ/N) system. Results Probl. Cell Differ. 46 (2008) 1-25
8. Collingridge G.L., Kehl S.J., and McLennan H. Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. J. Physiol. 334 (1983) 33-46
9. Counts S.E., Perez S.E., and Mufson E.J. Galanin in Alzheimer's disease: neuroinhibitory or neuroprotective?. Cell. Mol. Life Sci. 65 (2008) 1842-1853
10. Crawley J.N. Minireview. Galanin-acetylcholine interactions: relevance to memory and Alzheimer's disease. Life Sci. 58 (1996) 2185-2199
11. Crawley J.N. Galanin impairs cognitive abilities in rodents: relevance to Alzheimer's disease. Cell. Mol. Life Sci. 65 (2008) 1836-1841
12. Daumas S., Betourne A., Halley H., Wolfer D.P., Lipp H.P., Lassalle J.M., and Frances B. Transient activation of the CA3 Kappa opioid system in the dorsal hippocampus modulates complex memory processing in mice. Neurobiol. Learn. Mem. 88 (2007) 94-103
13. Day R., and Akil H. The posttranslational processing of prodynorphin in the rat anterior pituitary. Endocrinology 124 (1989) 2392-2405
14. de Wied D., Diamant M., and Fodor M. Central nervous system effects of the neurohypophyseal hormones and related peptides. Front. Neuroendocrinol. 14 (1993) 251-302
15. De Wied D., and Burbach J.P.H. Neuropeptides and behavior. In: Adelman G., and Smith B.H. (Eds). Encyclopedia of Neuroscience Vol. 2 (1999), Elsevier, Amsterdam 1431-1436
16. De Wied D., and Sigling H.O. Neuropeptides involved in the pathophysiology of schizophrenia and major depression. Neurotox. Res. 4 (2002) 453-468
17. Diez M., Danner S., Frey P., Sommer B., Staufenbiel M., Wiederhold K.H., and Hökfelt T. Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta-amyloid precursor protein (APP) with the Swedish double mutation (APP23). Neurobiol. Dis. 14 (2003) 579-594
18. Dudek S.M., and Bear M.F. Homosynaptic long-term depression in area CA1 of hippocampus and effects of N-methyl-d-aspartate receptor blockade. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 4363-4367
19. Dutar P., Lamour Y., and Nicoll R.A. Galanin blocks the slow cholinergic EPSP in CA1 pyramidal neurons from ventral hippocampus. Eur. J. Pharmacol. 164 (1989) 355-360
20. Eichenbaum H. Declarative memory: insights from cognitive neurobiology. Annu. Rev. Psychol. 48 (1997) 547-572
21. Elliott-Hunt C.R., Marsh B., Bacon A., Pope R., Vanderplank P., and Wynick D. Galanin acts as a neuroprotective factor to the hippocampus. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 5105-5110
22. Elliott-Hunt C.R., Pope R.J., Vanderplank P., and Wynick D. Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage. J. Neurochem. 100 (2007) 780-789
23. Elvander E., Schött P.A., Sandin J., Bjelke B., Kehr J., Yoshitake T., and Ögren S.O. Intraseptal muscarinic ligands and galanin: influence on hippocampal acetylcholine and cognition. Neuroscience 126 (2004) 541-557
24. Fibiger H.C. Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci. 14 (1991) 220-223
25. Gainer H. The biology of neurosecretory neurons. Adv. Biochem. Psychopharmacol. 28 (1981) 5-20
26. Gavioli E.C., and Calo G. Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands. Naunyn Schmiedebergs Arch. Pharmacol. 372 (2006) 319-330
27. Gottsch M.L., Zeng H., Hohmann J.G., Weinshenker D., Clifton D.K., and Steiner R.A. Phenotypic analysis of mice deficient in the type 2 galanin receptor (GALR2). Mol. Cell. Biol. 25 (2005) 4804-4811
28. Heilig M., Koob G.F., Ekman R., and Britton K.T. Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci. 17 (1994) 80-85
29. Higgins G.A., Kew J.N., Richards J.G., Takeshima H., Jenck F., Adam G., Wichmann J., Kemp J.A., and Grottick A.J. A combined pharmacological and genetic approach to investigate the role of orphanin FQ in learning and memory. Eur. J. NeuroSci. 15 (2002) 911-922
30. Hiramatsu M., and Inoue K. Des-tyrosine(1) dynorphin A-(2-13) improves carbon monoxide-induced impairment of learning and memory in mice. Brain Res. 859 (2000) 303-310
31. Hökfelt T., Broberger C., Xu Z.Q., Sergeyev V., Ubink R., and Diez M. Neuropeptides - an overview. Neuropharmacology 39 (2000) 1337-1356
32. Hökfelt T., Bartfai T., and Bloom F. Neuropeptides: opportunities for drug discovery. Lancet Neurol. 2 (2003) 463-472
33. Hökfelt T., and Mutt V. Neuropeptides. In: Adelman G., and Smith B.H. (Eds). Encyclopedia of Neuroscience Vol. 2 (1999), Elsevier, Amsterdam 1423-1429
34. Holmes A., Yang R.J., and Crawley J.N. Evaluation of an anxiety-related phenotype in galanin overexpressing transgenic mice. J. Mol. Neurosci. 18 (2002) 151-165
35. Huge V., Rammes G., Beyer A., Zieglgansberger W., and Azad S.C. Activation of kappa opioid receptors decreases synaptic transmission and inhibits long-term potentiation in the basolateral amygdala of the mouse. Eur. J. Pain 13 (2009) 124-129
36. Iismaa T.P., and Shine J. Galanin and galanin receptors. Results Probl. Cell Differ. 26 (1999) 257-291
37. Jenck F., Moreau J.L., Martin J.R., Kilpatrick G.J., Reinscheid R.K., Monsma Jr. F.J., Nothacker H.P., and Civelli O. Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 14854-14858
38. Kehr J., Yoshitake T., Wang F.H., Razani H., Gimenez-Llort L., Jansson A., Yamaguchi M., and Ögren S.O. Galanin is a potent in vivo modulator of mesencephalic serotonergic neurotransmission. Neuropsychopharmacology 27 (2002) 341-356
39. Kinney J.W., Starosta G., Holmes A., Wrenn C.C., Yang R.J., Harris A.P., Long K.C., and Crawley J.N. Deficits in trace cued fear conditioning in galanin-treated rats and galanin-overexpressing transgenic mice. Learn. Mem. 9 (2002) 178-190
40. Kinney J.W., Sanchez-Alavez M., Barr A.M., Criado J.R., Crawley J.N., Behrens M.M., Henriksen S.J., and Bartfai T. Impairment of memory consolidation by galanin correlates with in vivo inhibition of both LTP and CREB phosphorylation. Neurobiol. Learn. Mem. (2009) 10.1016/j.nlm.2009.06.005
41. Kölsch H., Wagner M., Bilkei-Gorzo A., Toliat M.R., Pentzek M., Fuchs A., Kaduszkiewicz H., van den Bussche H., Riedel-Heller S.G., Angermeyer M.C., Weyerer S., Werle J., Bickel H., Mosch E., Wiese B., Daerr M., Jessen F., Maier W., and Dichgans M. Gene polymorphisms in prodynorphin (PDYN) are associated with episodic memory in the elderly. J. Neural. Transm. 116 (2009) 897-903
42. Koob G.F., and Le Moal M. Addiction and the brain antireward system. Annu. Rev. Psychol. 59 (2008) 29-53
43. Kordower J.H., and Mufson E.J. Galanin-like immunoreactivity within the primate basal forebrain: differential staining patterns between humans and monkeys. J. Comp. Neurol. 294 (1990) 281-292
44. Köster A., Montkowski A., Schulz S., Stube E.M., Knaudt K., Jenck F., Moreau J.L., Nothacker H.P., Civelli O., and Reinscheid R.K. Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 10444-10449
45. Kreek M.J., LaForge K.S., and Butelman E. Pharmacotherapy of addictions. Nat. Rev. Drug. Discov. 1 (2002) 710-726
46. Kuteeva E., Calza L., Holmberg K., Theodorsson E., Ögren S.O., and Hökfelt T. Distribution of galanin and galanin transcript in the brain of a galanin-overexpressing transgenic mouse. J. Chem. Neuroanat. 28 (2004) 185-216
47. Kuteeva E., Hökfelt T., and Ögren S.O. Behavioural characterisation of young adult transgenic mice overexpressing galanin under the PDGF-B promoter. Regul. Pept. 125 (2005) 67-78
48. Kuteeva E., Wardi T., Hökfelt T., and Ögren S.O. Galanin enhances and a galanin antagonist attenuates depression-like behaviour in the rat. Eur. Neuropsychopharmacol. 17 (2007) 64-69
49. Kuteeva E., Wardi T., Lundström L., Sollenberg U., Langel U., Hökfelt T., and Ögren S.O. Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/stress-related genes at the cell body level. Neuropsychopharmacology 33 (2008) 2573-2585
50. Kuzmin A., Madjid N., Terenius L., Ögren S.O., and Bakalkin G. Big dynorphin, a prodynorphin-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice. Neuropsychopharmacology 31 (2006) 1928-1937
51. Kuzmin A., Kreek M.J., Bakalkin G., and Liljequist S. The nociceptin/orphanin FQ receptor agonist Ro 64-6198 reduces alcohol self-administration and prevents relapse-like alcohol drinking. Neuropsychopharmacology 32 (2007) 902-910
52. Kuzmin A., Madjid N., Johansson B., Terenius L., and Ögren S.O. The nociceptin system and hippocampal cognition in mice. A pharmacological and genetic analysis. Brain. Res. (2009) 10.1016/j.brainres.2009.09.075
53. Land B.B., Bruchas M.R., Lemos J.C., Xu M., Melief E.J., and Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J. Neurosci. 28 (2008) 407-414
54. Lu X., Barr A.M., Kinney J.W., Sanna P., Conti B., Behrens M.M., and Bartfai T. A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 874-879
55. Lu X., Lundström L., Langel U., and Bartfai T. Galanin receptor ligands. Neuropeptides 39 (2005) 143-146
56. Lu X., Ross B., Sanchez-Alavez M., Zorrilla E.P., and Bartfai T. Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. Neuropeptides 42 (2008) 387-397
57. Ludwig M., and Leng G. Dendritic peptide release and peptide-dependent behaviours. Nat. Rev. Neurosci. 7 (2006) 126-136
58. Manabe T., Noda Y., Mamiya T., Katagiri H., Houtani T., Nishi M., Noda T., Takahashi T., Sugimoto T., Nabeshima T., and Takeshima H. Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors. Nature 394 (1998) 577-581
59. Mazarati A.M., Hohmann J.G., Bacon A., Liu H., Sankar R., Steiner R.A., Wynick D., and Wasterlain C.G. Modulation of hippocampal excitability and seizures by galanin. J. Neurosci. 20 (2000) 6276-6281
60. McDaniel K.L., Mundy W.R., and Tilson H.A. Microinjection of dynorphin into the hippocampus impairs spatial learning in rats. Pharmacol. Biochem. Behav. 35 (1990) 429-435
61. McDonald M.P., and Crawley J.N. Galanin receptor antagonist M40 blocks galanin-induced choice accuracy deficits on a delayed-nonmatching-to-position task. Behav. Neurosci. 110 (1996) 1025-1032
62. McGinty J.F., Henriksen S.J., Goldstein A., Terenius L., and Bloom F.E. Dynorphin is contained within hippocampal mossy fibers: immunochemical alterations after kainic acid administration and colchicine-induced neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 80 (1983) 589-593
63. McMillan P.J., Peskind E., Raskind M.A., and Leverenz J.B. Increased galanin receptor occupancy in Alzheimer's disease. Neurobiol. Aging 25 (2004) 1309-1314
64. Melander T., Staines W.A., Hökfelt T., Rökaeus A., Eckenstein F., Salvaterra P.M., and Wainer B.H. Galanin-like immunoreactivity in cholinergic neurons of the septum-basal forebrain complex projecting to the hippocampus of the rat. Brain Res. 360 (1985) 130-138
65. Melander T., Hökfelt T., Rökaeus A., Cuello A.C., Oertel W.H., Verhofstad A., and Goldstein M. Coexistence of galanin-like immunoreactivity with catecholamines, 5-hydroxytryptamine, GABA and neuropeptides in the rat CNS. J. Neurosci. 6 (1986) 3640-3654
66. Melander T., Staines W.A., and Rökaeus A. Galanin-like immunoreactivity in hippocampal afferents in the rat, with special reference to cholinergic and noradrenergic inputs. Neuroscience 19 (1986) 223-240
67. Melander T., Köhler C., Nilsson S., Hökfelt T., Brodin E., Theodorsson E., and Bartfai T. Autoradiographic quantitation and anatomical mapping of 125I-galanin binding sites in the rat central nervous system. J. Chem. Neuroanat. 1 (1988) 213-233
68. Meunier J.C. Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. Eur. J. Pharmacol. 340 (1997) 1-15
69. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., and Monsarrat B. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 532-535
70. Micheau J.V., and Marrewijk B. Stimulation of 5-HT1A receptors by systemic or medial septum injection induces anxiogenic-like effects and facilitates acquisition of a spatial discrimination task in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 23 (1999) 1113-1133
71. Morilak D.A., Cecchi M., and Khoshbouei H. Interactions of norepinephrine and galanin in the central amygdala and lateral bed nucleus of the stria terminalis modulate the behavioral response to acute stress. Life Sci. 73 (2003) 715-726
72. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11 (1984) 47-60
73. Morris R.G., Anderson E., Lynch G.S., and Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist, AP5. Nature 319 (1986) 774-776
74. Morris R.G., Hagan J.J., and Rawlins J.N. Allocentric spatial learning by hippocampectomised rats: a further test of the "spatial mapping" and "working memory" theories of hippocampal function. Q. J. Exp. Psychol. B. 38 (1986) 365-395
75. Mufson E.J., Cochran E., Benzing W., and Kordower J.H. Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the stria terminalis in aging, Alzheimer's disease and Down's syndrome. Dementia 4 (1993) 237-250
76. Nabeshima T., Noda Y., and Mamiya T. The role of nociceptin in cognition. Brain Res. 848 (1999) 167-173
77. Neal Jr. C.R., Mansour A., Reinscheid R., Nothacker H.P., Civelli O., and Watson Jr. S.J. Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J. Comp. Neurol. 406 (1999) 503-547
78. Nguyen X.V., Masse J., Kumar A., Vijitruth R., Kulik C., Liu M., Choi D.Y., Foster T.C., Usynin I., Bakalkin G., and Bing G. Prodynorphin knockout mice demonstrate diminished age-associated impairment in spatial water maze performance. Behav. Brain Res. 161 (2005) 254-262
79. Noda Y., Mamiya T., Manabe T., Nishi M., Takeshima H., and Nabeshima T. Role of nociceptin systems in learning and memory. Peptides 21 (2000) 1063-1069
80. O'Donnell D., Mennicken F., Hoffert C., Hubatsch D., Pelletier M., Walker P., and Ahmad S. Localization of galanin receptor subtypes in the rat CNS. In: Quirion R., Björklund A., and Hökfelt T. (Eds). Handbook of Chemical Neuroanatomy, Peptide Receptors, Part II Vol. 20 (2003), Elsevier, Amsterdam 195-244
81. O'Meara G., Coumis U., Ma S.Y., Kehr J., Mahoney S., Bacon A., Allen S.J., Holmes F., Kahl U., Wang F.H., Kearns I.R., Ove-Ögren S., Dawbarn D., Mufson E.J., Davies C., Dawson G., and Wynick D. Galanin regulates the postnatal survival of a subset of basal forebrain cholinergic neurons. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 11569-11574
82. Ögren S.O., Hökfelt T., Kask K., Langel U., and Bartfai T. Evidence for a role of the neuropeptide galanin in spatial learning. Neuroscience 51 (1992) 1-5
83. Ögren S.O., Kehr J., and Schött P.A. Effects of ventral hippocampal galanin on spatial learning and on in vivo acetylcholine release in the rat. Neuroscience 75 (1996) 1127-1140
84. Ögren S.O., Schött P.A., Kehr J., Yoshitake T., Misane I., Mannström P., and Sandin J. Modulation of acetylcholine and serotonin transmission by galanin. Relationship to spatial and aversive learning. Ann. N. Y. Acad. Sci. 863 (1998) 342-363
85. Ögren S.O., Kuteeva E., Hökfelt T., and Kehr J. Galanin receptor antagonists: a potential novel pharmacological treatment for mood disorders. CNS Drugs 20 (2006) 633-654
86. Ögren S.O., Eriksson T.M., Elvander-Tottie E., D'Addario C., Ekström J.C., Svenningsson P., Meister B., Kehr J., and Stiedl O. The role of 5-HT(1A) receptors in learning and memory. Behav. Brain Res. 195 (2008) 54-77
87. Pirondi S., D'Intino G., Gusciglio M., Massella A., Giardino L., Kuteeva E., Ögren S.O., Hökfelt T., and Calza L. Changes in brain cholinergic markers and spatial learning in old galanin-overexpressing mice. Brain Res. 1138 (2007) 10-20
88. Redrobe J.P., Calo G., Guerrini R., Regoli D., and Quirion R. [Nphe(1)]-Nociceptin (1-13)-NH(2), a nociceptin receptor antagonist, reverses nociceptin-induced spatial memory impairments in the Morris water maze task in rats. Br. J. Pharmacol. 131 (2000) 1379-1384
89. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma Jr. F.J., and Civelli O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270 (1995) 792-794
90. Robinson J.K., and Crawley J.N. Intraventricular galanin impairs delayed nonmatching-to-sample performance in rats. Behav. Neurosci. 107 (1993) 458-467
91. Rodriguez-Puertas R., Nilsson S., Pascual J., Pazos A., and Hökfelt T. 125I-galanin binding sites in Alzheimer's disease: increases in hippocampal subfields and a decrease in the caudate nucleus. J. Neurochem. 68 (1997) 1106-1113
92. Rustay N.R., Wrenn C.C., Kinney J.W., Holmes A., Bailey K.R., Sullivan T.L., Harris A.P., Long K.C., Saavedra M.C., Starosta G., Innerfield C.E., Yang R.J., Dreiling J.L., and Crawley J.N. Galanin impairs performance on learning and memory tasks: findings from galanin transgenic and GAL-R1 knockout mice. Neuropeptides 39 (2005) 239-243
93. Sandin J., Georgieva J., Schött P.A., Ögren S.O., and Terenius L. Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats. Eur. J. NeuroSci. 9 (1997) 194-197
94. Sandin J., Nylander I., Georgieva J., Schött P.A., Ögren S.O., and Terenius L. Hippocampal dynorphin B injections impair spatial learning in rats: a kappa-opioid receptor-mediated effect. Neuroscience 85 (1998) 375-382
95. Sandin J., Ögren S.O., and Terenius L. Nociceptin/orphanin FQ modulates spatial learning via ORL-1 receptors in the dorsal hippocampus of the rat. Brain Res. 997 (2004) 222-233
96. Schött P.A., Bjelke B., and Ögren S.O. Distribution and kinetics of galanin infused into the ventral hippocampus of the rat: relationship to spatial learning. Neuroscience 83 (1998) 123-136
97. Schött P.A., Bjelke B., and Ögren S.O. Time-dependent effects of intrahippocampal galanin on spatial learning. Relationship to distribution and kinetics. Ann. N. Y. Acad. Sci. 863 (1998) 454-456
98. Schött P.A., Hökfelt T., and Ögren S.O. Galanin and spatial learning in the rat. Evidence for a differential role for galanin in subregions of the hippocampal formation. Neuropharmacology 39 (2000) 1386-1403
99. Schwarzer C. 30 years of dynorphins - new insights on their functions in neuropsychiatric diseases. Pharmacol. Ther. 123 (2009) 353-370
100. Simmons M.L., and Chavkin C. Endogenous opioid regulation of hippocampal function. Int. Rev. Neurobiol. 39 (1996) 145-196
101. Skofitsch G., and Jacobowitz D.M. Immunohistochemical mapping of galanin-like neurons in the rat central nervous system. Peptides 6 (1985) 509-546
102. Steiner R.A., Hohmann J.G., Holmes A., Wrenn C.C., Cadd G., Jureus A., Clifton D.K., Luo M., Gutshall M., Ma S.Y., Mufson E.J., and Crawley J.N. Galanin transgenic mice display cognitive and neurochemical deficits characteristic of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4184-4189
103. Swanson C.J., Blackburn T.P., Zhang X., Zheng K., Xu Z.Q., Hökfelt T., Wolinsky T.D., Konkel M.J., Chen H., Zhong H., Walker M.W., Craig D.A., Gerald C.P., and Branchek T.A. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (GAL3) antagonists SNAP 37889 and SNAP 398299. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 17489-17494
104. Tallent M.K. Presynaptic inhibition of glutamate release by neuropeptides: use-dependent synaptic modification. Results Probl. Cell Differ. 44 (2008) 177-200
105. Tatemoto K., Rökaeus A., Jörnvall H., McDonald T.J., and Mutt V. Galanin - a novel biologically active peptide from porcine intestine. FEBS Lett. 164 (1983) 124-128
106. Weiss J.M., Bonsall R.W., Demetrikopoulos M.K., Emery M.S., and West C.H. Galanin: a significant role in depression?. Ann. N. Y. Acad. Sci. 863 (1998) 364-382
107. Weiss J.M., Boss-Williams K.A., Moore J.P., Demetrikopoulos M.K., Ritchie J.C., and West C.H. Testing the hypothesis that locus coeruleus hyperactivity produces depression-related changes via galanin. Neuropeptides 39 (2005) 281-287
108. Wrenn C.C., Marriott L.K., Kinney J.W., Holmes A., Wenk G.L., and Crawley J.N. Galanin peptide levels in hippocampus and cortex of galanin-overexpressing transgenic mice evaluated for cognitive performance. Neuropeptides 36 (2002) 413-426
109. Wrenn C.C., Kinney J.W., Marriott L.K., Holmes A., Harris A.P., Saavedra M.C., Starosta G., Innerfield C.E., Jacoby A.S., Shine J., Iismaa T.P., Wenk G.L., and Crawley J.N. Learning and memory performance in mice lacking the GAL-R1 subtype of galanin receptor. Eur. J. NeuroSci. 19 (2004) 1384-1396
110. Xu Z.Q., Shi T.J., and Hökfelt T. Galanin/GMAP- and NPY-like immunoreactivities in locus coeruleus and noradrenergic nerve terminals in the hippocampal formation and cortex with notes on the galanin-R1 and -R2 receptors. J. Comp. Neurol. 392 (1998) 227-251
111. Xu Z.Q., Zhang X., Pieribone V.A., Grillner S., and Hökfelt T. Galanin-5-hydroxytryptamine interactions: electrophysiological, immunohistochemical and in situ hybridization studies on rat dorsal raphe neurons with a note on galanin R1 and R2 receptors. Neuroscience 87 (1998) 79-94
112. Yakovleva T., Marinova Z., Kuzmin A., Seidah N.G., Haroutunian V., Terenius L., and Bakalkin G. Dysregulation of dynorphins in Alzheimer disease. Neurobiol. Aging 28 (2007) 1700-1708
113. Yoshitake T., Reenila I., Ögren S.O., Hökfelt T., and Kehr J. Galanin attenuates basal and antidepressant drug-induced increase of extracellular serotonin and noradrenaline levels in the rat hippocampus. Neurosci. Lett. 339 (2003) 239-242
114. Yoshitake T., Wang F.H., Kuteeva E., Holmberg K., Yamaguchi M., Crawley J.N., Steiner R., Bartfai T., Ögren S.O., Hökfelt T., and Kehr J. Enhanced hippocampal noradrenaline and serotonin release in galanin-overexpressing mice after repeated forced swimming test. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 354-359
115. Zini S., Roisin M.P., Langel U., Bartfai T., and Ben-Ari Y. Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus. Eur. J. Pharmacol. 245 (1993) 1-7